← Back to Clinical Trials
Recruiting NCT07042243

NCT07042243 The Florida ASCENT Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07042243
Status Recruiting
Phase
Sponsor University of Florida
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2025-12-05
Primary Completion 2027-08

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type INTERVENTIONAL
Interventions
MyCarePulse and ASCENT PN

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2025-12-05 with a primary completion date of 2027-08.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical trial is to adapt, implement, and evaluate MyCarePulse and ASCENT patient navigator to overcome barriers to care among patients with cancer. The main hypotheses it aims to test are: * At the patient level, the intervention will result in higher levels of food security, self- efficacy for dietary behaviors, and higher diet quality than standard care. * At the provider level, the intervention will be feasible, acceptable, appropriate, and able to enhance individualized care for patient wellness. Researchers will compare cancer patients receiving the MyCarePulse and ASCENT patient navigator intervention to those receiving standard care, to see if the intervention improves food security, self-efficacy, and diet quality. Phase 1 Patient Participants will: * Complete the ASCENT Questionnaire, which is comprised of the following: * U.S. Food Security Survey Module (U.S. FSSM) * Patient-Reported Outcomes Measurement Information System (PROMIS-29) * Automated Self-Administered 24-Hour (ASA24®) Dietary Assessment Tool * Be assessed using the Veggie Meter instrument * Participate in two semi-structured interviews Provider Participants will: •Participate in one semi-structured interview Phase 2 Patient Participants will: * Participate in ASCENT patient navigator screenings and consultations * Complete the ASCENT Questionnaire, which comprises the U.S. FSSM, PROMIS-29, and ASA24®

Eligibility Criteria

Patient Eligibility Inclusion Criteria: 1. ≥18 years old. 2. Pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months. 3. Self-reported ability to read and speak English. 4. Able to provide informed consent. 5. Participant must not be considered a "vulnerable population" (pregnant women, neonates, children etc.) Patient Eligibility Exclusion Criteria: 1. ≤18 years old. 2. Participant do not have a pathologically confirmed diagnosis of colorectal, prostate, lung, breast, gynecologic, hematologic, or skin (including melanoma) cancer within the past 12 months. 3. Participant does not live within the state of Florida. 3\) Does not self-reported ability to read and speak English or Spanish. 4) Not able to provide informed consent. 5) Participant is considered a "vulnerable population" (pregnant women, neonates, children etc.) Provider Eligibility Inclusion Criteria 1. ≥18 years old. 2. Currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics. 3. Self-reported ability to read and speak English or Spanish. 4. Able to provide informed consent. 5. Participant must not be considered a "vulnerable population" (pregnant women, neonates, children etc.) Provider Eligibility Exclusion Criteria 1. ≤ 18 years old. 2. Does not currently works as a physician, physician assistant, patient navigator and/or health system/administrative leader in UF and UM affiliated clinics. 3. Does not self-report having the ability to read and speak English. 4. Not able to provide informed consent. 5. Participant is considered a "vulnerable population" (pregnant women, neonates, children etc.)

Contact & Investigator

Central Contact

Dejana Braithwaite, PhD, MSc

✉ dbraithwaite@surgery.ufl.edu

📞 4152165093

Frequently Asked Questions

Who can join the NCT07042243 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07042243 currently recruiting?

Yes, NCT07042243 is actively recruiting participants. Contact the research team at dbraithwaite@surgery.ufl.edu for enrollment information.

Where is the NCT07042243 trial being conducted?

This trial is being conducted at Gainesville, United States.

Who is sponsoring the NCT07042243 clinical trial?

NCT07042243 is sponsored by University of Florida. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology